ProPhase Labs에 대한 매도 수량은 투자자에게 ProPhase Labs의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

ProPhase Labs (NASDAQ:PRPH) 주식, 공매도 수량 보고

ProPhase Labs

ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.

Asset Sales

BLCO

FYBR

PRPH

WOLF

뉴 온 더 블록 아리 엠마누엘(Ari Emanuel)의 스포츠 및 엔터테인먼트 대기업인 엔데버 그룹 홀딩스(NYSE:EDR)는 마이애미 오픈 및 마드리드 오픈 테니스 토너먼트를 포함한 IMG 테니스 자산 매각 가능성을 검토하고 있다. IMG의 다른 자산 대부분은 UFC(얼티밋 파이팅 챔피언십) 및 WWE(월드 레슬링 엔터테인먼트)의 모회사인 TKO 그룹 홀딩스(NYSE:TKO)와의 목요일에 발표된 거래에 포함되었다.

딜 디스패치: UFC, WWE 모회사 TKO가 불 라이딩 인수; 엔데버가 테니스 자산 매각 검토 등

ProPhase Labs Inc

The Company will review on Thursday, December 12th, at 12:00 p.m. EST.
GARDEN CITY, NY, Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today provided updates on several key initiatives.
Securing Low-Interest Rate Financing from a Global Private Equity Fund
ProPhase has secured an agreement with a billion-dollar global private equity fund, providing flexible, low-interest rate debt financing as needed. Based on the current operating plans and financial forecasts, the Company believes that the aforementioned debt financing arrangement will eliminate the necessity for future equity financing in the near term and provides the Company with the strategic freedom to focus on and grow its core businesses until a meaningful liquidity event occurs and/or until the Company achieves profitability. Additionally, ProPhase will explore opportunities with the fund to distribute its ProPhase TK supplements—Legendz XL, Legendz Triple Edge, and the forthcoming Equivir—throughout Asia. Equivir is a clinically tested dietary supplement that serves as an immune booster, both prophylactically and therapeutically.
Pharmaloz Capacity Expansion and Major New Contract
The Company is entering the final phase of contract negotiations with a major lozenge brand. This partnership would fully utilize Pharmaloz's forthcoming high-tech production line #2, set to be one of North America's most advanced lines, offering enhanced automation, efficiency, and energy savings. For Line #1, the Company currently estimates a 12-month forward-looking run rate of $15+ million in revenues and a projected $5+ million in net earnings at Pharmaloz. The new contract, if consummated, would add up to $35 million in additional revenues annually. By late 2025, assuming full utilization of production lines #1 and #2, annualized revenue run-rates may approach $50 million, with projected net earnings of between $8 and $10 million entering 2026.
Strategic Executive Hiring
To support these Pharmaloz growth initiatives, ProPhase has hired Jay Schwartz, a 30-year veteran in the consumer health sector. Mr. Schwartz will play a key role in finalizing the large lozenge contract, overseeing the installation of line #2, and preparing it for full-scale utilization. Furthermore, he will assist the Company as we actively pursue strategic alternatives including a potential sale of Pharmaloz.
Implementing Significant Cost Reductions
ProPhase is finalizing a comprehensive set of cost-saving measures targeting its non-core operations. These efforts are expected to reduce operating expenses by at least $6 million per year without impacting core business units. These cost efficiencies will enable the Company to sharpen its focus on its key subsidiaries. Combined with anticipated revenue and earnings growth at Pharmaloz, and the ramp up of DNA Complete, DNA Expand and ProPhase Supplements, the Company is poised for substantial operational improvements in 2025.
Executive Perspective
"The partnership with this global private equity fund should secure, low-interest rate financing at our disposal, with the goal of eliminating discounted equity offerings in the near-term," said Ted Karkus, CEO of ProPhase Labs. "This capital access provides the foundation we need as we finalize a transformative lozenge contract growing revenues just at Pharmaloz from an estimated $15+ million run rate for 2025 to potentially $50 million for 2026. Hiring Jay Schwartz is just the first step in strengthening our management team to handle the increased scale and profitability. Finally, as we implement our significant cost-saving measures in the coming weeks, we are ensuring the Company's operational alignment for robust performance for not only Pharmaloz but for the entire Company in 2025 and in the years ahead."
The Company will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. Ted Karkus, Chairman &amp; Chief Executive Officer, will present on Thursday, December 12th, at 12:00 p.m. EST.

News

Management

Pharmaloz Announced Final Contract Negotiations With Major Lozenge Brand; New Partnership Could Add $35M Annually To Revenue By Late 2025, Bringing Total Revenue To $50M With Projected Net Earnings Of $8M-$10M In 2026;  Targets $6M Annual Savings Through Non-Core Operations Cost-Cutting Without Affecting Core Units

WIIM

ProPhase Labs shares are trading lower after the company reported worse-than-expected Q3 financial results.

Guidance

ProPhase Labs Anticipates 'Significant 'Sequential Improvement In Revenues And EBITDA In Q4 2024, And Beyond

Earnings

Earnings Misses

ProPhase Labs Q3 2024 GAAP EPS $(0.35) Misses $0.04 Estimate, Sales $3.146M Miss $23.850M Estimate

ACXP

ADAP

AEMD

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

BITF

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

BWEN

CAAS

CAPR

CREX

CRNT

CSAN

CSCO

CSLR

CSTE

CYBR

DADA

DGII

DMAC

DOLE

DRRX

DTCK

ECOR

EDBL

ENLT

EZPW

FORA

FPAY

FULC

GILT

GLAD

GOEV

GRYP

HIVE

HROW

HYZN

IBTA

ICAD

ICCC

INLX

INVZ

JAGX

JJSF

KBDC

KLIC

KMDA

KRMD

KULR

LMFA

LOAR

LQDA

LUCD

LVLU

MCRB

MPTI

MRSN

NTWK

NXGL

OMER

OPRX

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-11-13. Here's a quick overview of what investors should know before the release.
Analysts are estimating that ProPhase Labs will report an earnings per share (EPS) of $0.04.
The market awaits ProPhase Labs's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
The company's EPS missed by $0.09 in the last quarter, leading to a 9.6% drop in the share price on the following day.
Here's a look at ProPhase Labs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.24</td>
<td>-0.28</td>
<td>-0.26</td>
<td>-0.19</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.33</td>
<td>-0.07</td>
<td>-0.51</td>
<td>-0.30</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-10.0%</td>
<td>3.0%</td>
<td>4.0%</td>
<td>-11.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731445398_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of ProPhase Labs were trading at $0.739 as of November 11. Over the last 52-week period, shares are down 83.22%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/PRPH/earnings">To track all earnings releases for ProPhase Labs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ProPhase Labs's Earnings: A Preview

<h3>Gainers</h3>
<ul>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares increased by 75.3% to $0.46 during Friday's pre-market session. The company's market cap stands at $2.8 million. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) stock rose 29.94% to $56.42. The company's market cap stands at $10.4 billion. As per the press release, Q2 earnings came out yesterday. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) stock rose 26.31% to $22.8. The market value of their outstanding shares is at $2.0 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Tenaya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>) shares moved upwards by 20.39% to $3.01. The company's market cap stands at $237.4 million. The company's, Q3 earnings came out 2 days ago. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) stock rose 15.11% to $1.37. The company's market cap stands at $13.9 million. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares rose 14.99% to $1.15. The company's market cap stands at $89.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock declined by 51.8% to $0.69 during Friday's pre-market session. The company's market cap stands at $13.1 million. </li>
<li>Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) stock decreased by 40.06% to $4.7. The market value of their outstanding shares is at $665.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock decreased by 38.75% to $15.05. The market value of their outstanding shares is at $1.7 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock fell 33.34% to $1.86. The market value of their outstanding shares is at $765.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) shares declined by 29.7% to $0.69. The market value of their outstanding shares is at $79.6 million. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) shares decreased by 25.61% to $4.3. The company's market cap stands at $447.9 million. The company's, Q3 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALVR

CTMX

DOCS

FTRE

INDP

MRVI

RVNC

TIVC

TNYA

12 Health Care Stocks Moving In Friday's Pre-Market Session

U.S. stocks traded higher toward the end of trading, with the S&amp;P 500 gaining around 0.6% on Friday.
The Dow traded up 0.83% to 44,092.10 while the NASDAQ rose 0.20% to 19,308.79. The S&amp;P 500 also rose, gaining, 0.60% to 6,009.11.
Check This Out: <a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a>
Leading and Lagging Sectors Consumer staples shares surged by 1.8% on Friday.
In trading on Friday, materials shares fell by 1%.
Top Headline
The total number of active U.S. oil rigs came in unchanged at 479 rigs this week, Baker Hughes Inc reported.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Sezzle Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) shares shot up 71% to $429.31 after the company reported a year-over-year increase in third-quarter financial results, raised its FY24 guidance, and issued FY25 adjusted EPS guidance above estimates.</li>
<li>Shares of Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) got a boost, surging 54% to $27.55 after the company reported better-than-expected third-quarter revenue results.</li>
<li>indie Semiconductor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) shares were also up, gaining 49% to $5.11 after the company reported better-than-expected third-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares dropped 45% to $0.78 after the company reported the pricing of public offering of common stock.</li>
<li>Shares of Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) were down 45% to $13.59 after the company reported worse-than-expected third-quarter financial results.</li>
<li>Nature&#8217;s Miracle Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) was down, falling 30% to $0.1038 after the company announced a $3 million public offering.</li>
</ul>
Commodities In commodity news, oil traded down 2.9% to $70.28 while gold traded down 0.5% at $2,692.30.
Silver traded down 1.5% to $31.385 on Friday, while copper fell 2.9% to $4.3040.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.65%, Germany's DAX fell 0.76% and France's CAC 40 fell 1.17%. Spain's IBEX 35 Index fell 0.16%, while London's FTSE 100 fell 0.84%.
The trade gap in France increased to €8.3 billion in September versus a revised €7.7 billion gap in the previous month, while current account deficit increased to €2.1 billion in September.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 gaining 0.30%, Hong Kong's Hang Seng Index falling 1.07%, China's Shanghai Composite Index dipping 0.53% and India's BSE Sensex falling 0.07%.
Foreign exchange reserves held by the Reserve Bank of India declined to $682.1 billion as of Nov. 1. China reported a current account surplus of $149.6 billion during the third quarter compared to the $60.8 billion surplus in the year-ago period. Japan&#8217;s household spending declined by 1.1% year-over-year in September.
Economics
<ul>
<li>The University of Michigan consumer sentiment rose to 73 in November, recording the highest reading in seven months, versus a reading of 70.5 in October and also topping market estimates of 71.</li>
<li>The total number of active U.S. oil rigs came in unchanged at 479 rigs this week, Baker Hughes Inc reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/dividends/24/11/41843561/wall-streets-most-accurate-analysts-spotlight-on-3-tech-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Tech Stocks With Over 3% Dividend Yields</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AAOI

INDI

NMHI

SEZL

S&P 500 Tops 6,000; Sezzle Shares Spike Higher

U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining more than 250 points on Friday.
The Dow traded up 0.62% to 44,001.69 while the NASDAQ fell 0.01% to 19,268.55. The S&amp;P 500 also rose, gaining, 0.40% to 5,997.19.
Check This Out: <a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a>
Leading and Lagging Sectors Utilities shares surged by 1.6% on Friday.
In trading on Friday, materials shares fell by 0.8%.
Top Headline
The University of Michigan consumer sentiment rose to 73 in November, recording the highest reading in seven months, versus a reading of 70.5 in October and also topping market estimates of 71.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Sezzle Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) shares shot up 65% to $413.71 after the company reported a year-over-year increase in third-quarter financial results, raised its FY24 guidance, and issued FY25 adjusted EPS guidance above estimates.</li>
<li>Shares of Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) got a boost, surging 47% to $26.38 after the company reported better-than-expected third-quarter revenue results.</li>
<li>indie Semiconductor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) shares were also up, gaining 46% to $5.02 after the company reported better-than-expected third-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares dropped 46% to $0.7752 after the company reported the pricing of public offering of common stock.</li>
<li>Shares of Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) were down 43% to $13.94 after the company reported worse-than-expected third-quarter financial results.</li>
<li>Nature&#8217;s Miracle Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) was down, falling 34% to $0.0975 after the company announced a $3 million public offering.</li>
</ul>
Commodities In commodity news, oil traded down 2.7% to $70.40 while gold traded down 0.4% at $2,695.00.
Silver traded down 1.2% to $31.470 on Friday, while copper fell 2.9% to $4.3015.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.65%, Germany's DAX fell 0.76% and France's CAC 40 fell 1.17%. Spain's IBEX 35 Index fell 0.16%, while London's FTSE 100 fell 0.84%.
The trade gap in France increased to €8.3 billion in September versus a revised €7.7 billion gap in the previous month, while current account deficit increased to €2.1 billion in September.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 gaining 0.30%, Hong Kong's Hang Seng Index falling 1.07%, China's Shanghai Composite Index dipping 0.53% and India's BSE Sensex falling 0.07%.
Foreign exchange reserves held by the Reserve Bank of India declined to $682.1 billion as of Nov. 1. China reported a current account surplus of $149.6 billion during the third quarter compared to the $60.8 billion surplus in the year-ago period. Japan&#8217;s household spending declined by 1.1% year-over-year in September.
Economics
The University of Michigan consumer sentiment rose to 73 in November, recording the highest reading in seven months, versus a reading of 70.5 in October and also topping market estimates of 71.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/dividends/24/11/41843561/wall-streets-most-accurate-analysts-spotlight-on-3-tech-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Tech Stocks With Over 3% Dividend Yields</a></li>
</ul>

Dow Tops 44,000; US Consumer Sentiment Increases In November

ProPhase Labs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares are trading lower by 47% to 75 cents during Friday&#8217;s session. The company announced an underwritten public offering of 4.17 million shares of common stock at 72 cents per share, totaling <a href="https://www.benzinga.com/pressreleases/24/11/g41833527/prophase-labs-announces-pricing-of-public-offering-of-common-stock">approximately $3 million</a> before expenses and discounts.
The company also granted underwriters a 45-day option to purchase up to an additional 625,500 shares to cover over-allotments. The offering, set to close on November 12, is managed by ThinkEquity. 
ProPhase Labs says proceeds will fund working capital and general corporate purposes, including capital investments, product development, commercialization and potential acquisitions in diagnostics, genomics and consumer products.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41843928/bitcoin-etfs-saw-record-1-38-billion-inflows-on-thursday">Bitcoin ETFs Saw Record $1.38 Billion Inflows On Thursday</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PRPH has a 52-week high of $7.48 and a 52-week low of $0.66.

Why ProPhase Labs (PRPH) Stock Is Down 47% Today

<h3>Gainers</h3>
<ul>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock rose 39.8% to $0.36 during Friday's regular session. The market value of their outstanding shares is at $2.2 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) stock increased by 33.57% to $24.11. The market value of their outstanding shares is at $2.1 billion. As per the press release, Q3 earnings came out today. </li>
<li>Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) stock moved upwards by 32.05% to $20.39. The market value of their outstanding shares is at $358.7 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) shares increased by 21.59% to $3.2. The company's market cap stands at $83.1 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock rose 19.31% to $0.45. The market value of their outstanding shares is at $6.0 million. </li>
<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) stock increased by 18.7% to $3.3. The company's market cap stands at $217.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock fell 48.1% to $0.74 during Friday's regular session. The market value of their outstanding shares is at $14.1 million. </li>
<li>Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock fell 41.11% to $14.47. The company's market cap stands at $1.6 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) shares fell 37.31% to $4.92. The market value of their outstanding shares is at $695.7 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock fell 36.6% to $3.67. The company's market cap stands at $381.8 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock declined by 32.08% to $1.9. The market value of their outstanding shares is at $779.7 million. The company's, Q3 earnings came out yesterday. </li>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) stock decreased by 29.23% to $0.69. The market value of their outstanding shares is at $80.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BNOX

NOTV

RIGL

12 Health Care Stocks Moving In Friday's Intraday Session

ProPhase Labs shares are trading lower after the company announced a $3 million public offering of 4.17 million common shares at $0.72 per share.

U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 0.2% on Friday.
Following the market opening Friday, the Dow traded up 0.20% to 43,817.98 while the NASDAQ fell 0.10% to 19,250.88. The S&amp;P 500 also rose, gaining, 0.13% to 5,981.13.
Check This Out: <a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a>
Leading and Lagging Sectors Utilities shares surged by 1% on Friday.
In trading on Friday, materials shares fell by 0.4%.
Top Headline
Fluor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) reported worse-than-expected third-quarter financial results and cuts its FY24 adjusted EBITDA guidance.
Fluor reported quarterly earnings of 51 cents per share which missed the analyst consensus estimate of 76 cents per share. The company reported quarterly sales of $4.094 billion which missed the analyst consensus estimate of $4.738 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Northann Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCL#NYSE">NCL</a>) shares shot up 122% to $0.4977.</li>
<li>Shares of Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) got a boost, surging 93% to $0.5030. Tivic Health&#xAE; Systems will report financial results on Thursday, Nov. 14 after market close.</li>
<li>FOXO Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#NYSE">FOXO</a>) shares were also up, gaining 66% to $0.6130.</li>
</ul>
Equities Trading DOWN
<ul>
<li>ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares dropped 52% to $0.69 after the company reported the pricing of public offering of common stock.</li>
<li>Shares of Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) were down 42% to $14.34 after the company reported worse-than-expected third-quarter financial results.</li>
<li>Nature&#8217;s Miracle Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) was down, falling 40% to $0.0891 after the company announced a $3 million public offering.</li>
</ul>
Commodities In commodity news, oil traded down 1.2% to $71.47 while gold traded up 0.1% at $2,709.70.
Silver traded up 0.2% to $31.915 on Friday, while copper fell 2% to $4.3430.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.5%, Germany's DAX fell 0.7% and France's CAC 40 fell 0.8%. Spain's IBEX 35 Index rose 0.1%, while London's FTSE 100 fell 0.6%.
The trade gap in France increased to €8.3 billion in September versus a revised €7.7 billion gap in the previous month, while current account deficit increased to €2.1 billion in September.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 gaining 0.30%, Hong Kong's Hang Seng Index falling 1.07%, China's Shanghai Composite Index dipping 0.53% and India's BSE Sensex falling 0.07%.
Foreign exchange reserves held by the Reserve Bank of India declined to $682.1 billion as of Nov. 1. China reported a current account surplus of $149.6 billion during the third quarter compared to the $60.8 billion surplus in the year-ago period. Japan&#8217;s household spending declined by 1.1% year-over-year in September.
Economics
The University of Michigan consumer sentiment index will be released today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/dividends/24/11/41843561/wall-streets-most-accurate-analysts-spotlight-on-3-tech-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Tech Stocks With Over 3% Dividend Yields</a></li>
</ul>

FOXO

Nuveen Insured California Premium Fund Ii

US Stocks Mixed; Fluor Earnings Miss Views

<h3>Gainers</h3>
<ul>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares rose 127.3% to $0.59 during Friday's pre-market session. The market value of their outstanding shares is at $3.6 million. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) stock moved upwards by 39.82% to $60.71. The market value of their outstanding shares is at $11.2 billion. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock moved upwards by 14.42% to $1.19. The market value of their outstanding shares is at $52.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares increased by 13.97% to $0.55. The market value of their outstanding shares is at $47.4 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) shares rose 13.68% to $20.52. The market value of their outstanding shares is at $1.8 billion. The company's, Q3 earnings came out today. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares moved upwards by 12.99% to $1.13. The market value of their outstanding shares is at $88.2 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares declined by 51.0% to $0.7 during Friday's pre-market session. The market value of their outstanding shares is at $13.3 million. </li>
<li>Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock decreased by 35.5% to $15.85. The market value of their outstanding shares is at $1.8 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) shares fell 31.9% to $1.9. The company's market cap stands at $781.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) shares declined by 28.19% to $5.63. The market value of their outstanding shares is at $796.9 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) shares fell 15.23% to $4.9. The market value of their outstanding shares is at $510.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) shares fell 14.42% to $0.84. The company's market cap stands at $96.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EYEN

<h3>Gainers</h3>
<ul>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock moved upwards by 127.3% to $0.59 during Friday's pre-market session. The market value of their outstanding shares is at $3.6 million. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares moved upwards by 39.82% to $60.71. The company's market cap stands at $11.2 billion. As per the press release, Q2 earnings came out yesterday. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares increased by 14.42% to $1.19. The market value of their outstanding shares is at $52.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares increased by 13.97% to $0.55. The market value of their outstanding shares is at $47.4 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) shares increased by 13.68% to $20.52. The company's market cap stands at $1.8 billion. The company's, Q3 earnings came out today. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares increased by 12.99% to $1.13. The market value of their outstanding shares is at $88.2 million. As per the press release, Q3 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares fell 51.0% to $0.7 during Friday's pre-market session. The market value of their outstanding shares is at $13.3 million. </li>
<li>Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock fell 35.5% to $15.85. The market value of their outstanding shares is at $1.8 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock declined by 31.9% to $1.9. The market value of their outstanding shares is at $781.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) shares fell 28.19% to $5.63. The company's market cap stands at $796.9 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock declined by 15.23% to $4.9. The market value of their outstanding shares is at $510.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) shares decreased by 14.42% to $0.84. The market value of their outstanding shares is at $96.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Shares of Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/11/41828267/upstart-stock-soars-after-strong-q3-results-details">third-quarter financial results</a>.
Upstart reported quarterly losses of seven cents per share which beat the analyst consensus estimate for losses of 15 cents. Quarterly revenue came in at $162.14 million which beat the analyst consensus estimate of $150.22 million and is an increase over sales of $134.55 million from the same period last year.
Upstart shares jumped 23.1% to $68.29 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>DevvStream Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEVS#NASDAQ">DEVS</a>) gained 370% to $4.85 in pre-market trading after dipping around 58% on Thursday.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) rose 52.8% to $0.4010 in pre-market trading. Tivic Health&#xAE; Systems will report financial results on Thursday, Nov, 14, after the closing bell.</li>
<li>Doximity, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares surged 44.2% to $62.60 in pre-market trading following better-than-expected second-quarter financial results.</li>
<li>Li-Cycle Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LICY#NYSE">LICY</a>) gained 41% to $5.09 in pre-market trading after posting upbeat quarterly results.</li>
<li>Northann Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCL#NYSE">NCL</a>) climbed 37.6% to $0.3089 in pre-market trading after jumping around 12% on Thursday.</li>
<li>Innodata Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) shares rose 36.4% to $33.20 in pre-market trading after the company reported better-than-expected third-quarter financial results.</li>
<li>Nature&#8217;s Miracle Holding Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) gained 31.8% to $0.1953 in pre-market trading after jumping over 52% on Thursday.</li>
<li>Five9, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) gained 24.6% to $40.88 in pre-market trading after the company reported better-than-expected third-quarter financial results and issued FY24 guidance above estimates.</li>
<li>Lumentum Holdings Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) gained 24.3% to $91.54 in pre-market trading after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares tumbled 45.4% to $0.7800 in pre-market trading after the company announced the pricing of public offering of common stock.</li>
<li>Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) shares fell 33.6% to $16.31 in pre-market trading after the company reported worse-than-expected third-quarter financial results.</li>
<li>AtlasClear Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATCH#NYSE">ATCH</a>) dipped 31.8% to $0.1910 in pre-market trading after jumping over 55% on Thursday.</li>
<li>agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) shares fell 29% to $1.98 in pre-market trading after the company reported worse-than-expected quarterly revenue results.</li>
<li>Maravai LifeSciences Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) declined 26.6% to $5.75 in pre-market trading after the company reported worse-than-expected third-quarter financial results and cut its FY24 sales guidance.</li>
<li>MDJM Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDJH#NASDAQ">MDJH</a>) shares dipped 22.4% to $0.1511 in pre-market trading after jumping 30% on Thursday.</li>
<li>Earlyworks Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELWS#NASDAQ">ELWS</a>) fell 17% to $5.60 in pre-market trading after surging over 10% on Thursday.</li>
<li>Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) fell 15% to $35.87 in today's pre-market trading after the company reported worse-than-expected quarterly financial results.</li>
<li>Redfin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) fell 14.1% to $9.85 in pre-market trading after the company reported worse-than-expected third-quarter financial results.</li>
<li>Wag! Group Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PET#NYSE">PET</a>) fell 13.8% to $0.5487 in pre-market trading. Wag! will report third quarter 2024 financial results before the opening bell on Wednesday, Nov. 13.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Pre-Market Outlook

ATCH

DEVS

ELWS

FIVN

INOD

LICY

LITE

MDJH

RDFN

UPST

Why Upstart Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket

The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include capital expenditures, product development and commercialization expenditures, and acquisitions of companies, businesses, technologies and products within and outside the diagnostic services, genomics and consumer products industry.

Reported Earlier, ProPhase Labs Prices $3M Public Offering Of 4.17M Common Shares At $0.72/Share

ProPhase Labs shares are trading lower after the company announced its intention to sell shares through a public offering.

Offerings

ProPhase Labs Announced That Intends To Sell Shares Of Its Common Stock In An Underwritten Public Offering; Terms Not Disclosed

Introduces DNA Expand Subscription Platform to Enrich Existing DNA Ancestry Data with Comprehensive Health Insights
GARDEN CITY, NY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) (the "Company" or "ProPhase"), a next generation biotech, genomics, and diagnostics company, today announced the launch of DNA Complete, Inc., a wholly owned subsidiary, offering a groundbreaking direct-to-consumer DNA test that sequences virtually 100% of a customer's genome. This new service provides customers with in-depth insights into health, wellness, and ancestry.
DNA Complete – A New Paradigm in Direct-to-Consumer DNA Testing
<ul>
<li>Comprehensive Whole Genome Sequencing: Unlike traditional DNA Ancestry tests that analyze small snippets of DNA, DNA Complete offers a full genomic view, empowering customers with detailed health and wellness information alongside enhanced ancestry data.</li>
<li>Strategic Leadership Addition: ProPhase retained Stu Hollenshead, former Chief Business Officer and COO of Barstool Sports and current CEO of 10PMCurfew, to spearhead marketing efforts.</li>
<li>Influencer-Driven Marketing Campaign: A robust marketing initiative featuring top social media influencers is set to launch and aims to maximize reach and engagement.</li>
<li>Competitive Pricing and Robust Platform: DNA Complete is designed to offer a robust genetic user platform at competitive pricing which makes advanced genomic insights accessible to a wider audience.</li>
<li>Cutting-Edge Bioinformatics and Ancestry Analysis: The service leverages its advanced bioinformatics platform and introduces a proprietary, sophisticated ancestry platform.</li>
<li>Flexibility with Sample Processing: DNA Complete provides the flexibility to send samples to ProPhase Labs' other wholly owned subsidiary, Nebula Genomics, as well as other leading genetics labs, ensuring the highest quality results and efficient pricing and turnaround times.</li>
<li>Continuous Engagement Through Subscription: The DNA Complete subscription service ensures ongoing customer engagement by providing regular updates and new insights. The subscription model is a high margin business that we expect will create longer term cash flow.</li>
<li>Genetic Counseling Services: To enhance the value proposition, DNA Complete offers genetic counseling to help customers interpret their data effectively.</li>
</ul>
DNA Expand – Enhancing Existing DNA Ancestry Data
<ul>
<li>Effortless Data Upload: Consumers can easily upload their DNA data from other ancestry tests to unlock ProPhase's proprietary health and wellness reports.</li>
<li>Significant Data Expansion: Users' existing DNA files are amplified with 50 times more data than available through traditional DNA ancestry tests, delivering more in-depth insights without the need for additional sequencing.</li>
<li>Flexible Subscription Options: Monthly and yearly subscriptions are available, with new reports added regularly to keep customers informed.</li>
<li>Significant Target Market: A recent estimate indicates that more than 26 million people worldwide have undergone genetic ancestry testing by direct-to-consumer (DTC) companies.1</li>
<li>High Margins with Minimal Costs: We will offer a subscription at $49.95 annually. Since no new sequencing is required, the cost of goods sold is minimal (primarily the cost of IT) and the margins should be substantial. Over the next few years, with minimal market penetration we would therefore expect significant revenues, gross profit and longer-term cash flow. &nbsp;</li>
</ul>

Biotech

General

ProPhase Labs Launches DNA Complete, To Enrich Existing DNA Ancestry Data With Comprehensive Health Insights

ProPhase Labs plummets 21%, prices $3M equity offering

ThinkEquity acted as sole book running manager for the offering. Published first on TheFly – the ultimate source for real-time, market-moving break...

ProPhase Labs 4.17M share Spot Secondary priced at $.72

17:33 EST ProPhase Labs (PRPH) files $291.61M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving b...

ProPhase Labs files $291.61M mixed securities shelf

ProPhase Labs files for mixed shelf offering

ProPhase Labs reports mixed Q3 results; initiates Q424 soft outlook

Prophase Labs ( ($PRPH) ) has released its Q3 earnings. Here is a breakdown of the information Prophase Labs presented to its investors. ProPhase L...

ProPhase Labs: Strategic Moves for Future Growth

ProPhase Labs, Inc. (PRPH) Q3 2024 Earnings Call Transcript

ProPhase has secured an agreement with a billion-dollar global private equity fund, providing flexible, low-interest rate debt financing as needed....

ProPhase Labs secures private equity backing, nears lozenge deal

ProPhase is finalizing a comprehensive set of cost-saving measures targeting its non-core operations. These efforts are expected to reduce operatin...

ProPhase Labs finalizing set of cost-saving measures for non-core operations

ProPhase Labs secures private equity backing, nears lozenge deal, and plans cost-cutting measures

Press Releases

ProPhase Labs to Present at the 2024 ThinkEquity Conference

Health Care

ProPhase Labs Launches DNA Complete®: Transforming Direct-to-Consumer Genetic Testing for Health, Wellness, and Enhanced Ancestry

ProPhase Labs Announces Proposed Public Offering of Common Stock

ProPhase Labs Announces Pricing of Public Offering of Common Stock

ProPhase Labs Inc. to Present Third Quarter 2024 Financial Results on November 13, 2024

ProPhase Labs Announces Closing of Public Offering of Common Stock

ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2024

Analyst Ratings

Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)

Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision

ProPhase Labs Secures Global Private Equity Backing, Nears Major Lozenge Deal, Adds Seasoned Industry Expert, and Plans Significant Cost-Cutting Measures

Athira Pharma

Aytu BioPharma

Cara Therapeutics

Comments

ProPhase Labs

매도 수량

ProPhase Labs (NASDAQ:PRPH) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌